T. Doi

Trifluridine/tipiracil versus placebo for third or later lines of treatment in metastatic gastric cancer: an exploratory subgroup analysis from the TAGS study

E. Van Cutsem, J. Tabernero, P. Azcue, 2021, ESMO open.

Phase I dose-escalation study of the c-Met tyrosine kinase inhibitor SAR125844 in Asian patients with advanced solid tumors, including patients with MET-amplified gastric cancer

Hyo Song Kim, Y. Bang, Jin-Hee Ahn, 2017, Oncotarget.

Overall survival results from a phase III trial of trifluridine/tipiracil versus placebo in patients with metastatic gastric cancer refractory to standard therapies (TAGS).

G. Beretta, J. Tabernero, M. Alsina, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Comprehensive clinical and molecular characterization of claudin 18.2 expression in advanced gastric or gastroesophageal junction cancer

T. Yoshino, T. Kuwata, K. Shitara, 2023, ESMO open.

453O DS-7300 (B7-H3 DXd antibody-drug conjugate [ADC]) shows durable antitumor activity in advanced solid tumors: Extended follow-up of a phase I/II study

S. Piha-Paul, Shin-ichiro Takahashi, M. Awad, 2022, Annals of Oncology.

Phase I dose-escalation study of the c-Met tyrosine kinase inhibitor SAR125844 in Asian patients with advanced solid tumors, including patients with MET-amplified gastric cancer

Y. Bang, Jin-Hee Ahn, T. Kudo, 2017, Oncotarget.

Pooled safety analysis from phase III studies of trifluridine/tipiracil in patients with metastatic gastric or gastroesophageal junction cancer and metastatic colorectal cancer

E. Van Cutsem, J. Tabernero, R. Mayer, 2022, ESMO open.